Antihemophilic factor, human recombinant

Identification

Summary

Antihemophilic factor, human recombinant is a form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency.

Brand Names
Advate, Adynovate, Helixate, Kogenate, Kovaltry, Novoeight, Recombinate
Generic Name
Antihemophilic factor, human recombinant
DrugBank Accession Number
DB00025
Background

Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Blood factors
Protein Structure
Db00025
Protein Chemical Formula
C11794H18314N3220O3553S83
Protein Average Weight
264725.5 Da
Sequences
>DB00025 sequence
ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFN
IAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ
REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR
EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNR
SLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLL
MDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRF
DDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIG
RKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGI
TDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNME
RDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAG
VQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKH
KMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYE
DSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTDPWFAHRTPMP
KIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPSPGAIDSNNSLSEMTHFRPQ
LHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSSTSNNLISTIPSDNLAAGTDN
TSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSW
GKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSL
LIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSNKTTSSKNMEMVQQK
KEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEG
QNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEKKIQEEIEK
KETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRSLNDSTNR
TKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRALKQFRL
PLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSI
PQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQGAKK
NNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHI
YQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRPGKVPFLRVATESSAKTPSK
LLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINEGQNKP
EIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIY
DEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTD
GSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGA
EPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHT
NTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHA
INGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYP
GVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITAS
GQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQ
FIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRS
TLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWR
PQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKV
KVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY
Download FASTA Format
Synonyms
  • Antihemophilic factor (recombinant)
  • Antihemophilic factor recombinant
  • Antihemophilic factor, human recombinant
  • Antihemophilic factor, recombinant
  • Coagulation factor VIII, recombinant
  • Factor VIII (rDNA)
  • Factor VIII (Recombinant)
  • Factor VIII recombin
  • Factor VIII, recombinant
  • Human Factor VIII (Recombinant)
  • Human factor VIII recombinant
  • Octocog alfa
  • rAHF
  • Recombinant antihemophilic factor VIII
External IDs
  • BAY 14-2222
  • BAY 81-8973
  • BAY W 6240
  • BAY-14-2222
  • BAY-81-8973
  • BAY-W-6240
  • BAY81-8973

Pharmacology

Indication

For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Antihemophilic Factor binds factor IXa along with calcium and phospholipid, This complex converts factor X to factor Xa to facilitate clotting cascade.

Mechanism of action

Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia).

TargetActionsOrganism
ACoagulation factor X
activator
Humans
ACoagulation factor IX
cofactor
Humans
Avon Willebrand factor
binder
Humans
UPhytanoyl-CoA dioxygenase, peroxisomal
antagonist
Humans
UAsialoglycoprotein receptor 2
binder
Humans
U78 kDa glucose-regulated protein
chaperone
Humans
UCalreticulin
chaperone
Humans
UCalnexin
chaperone
Humans
UProtein ERGIC-53
chaperone
Humans
UProlow-density lipoprotein receptor-related protein 1
modulator
Humans
UMultiple coagulation factor deficiency protein 2
modulator
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

8.4-19.3 hrs

Clearance
  • 4.1 mL/h•kg [Previously treated pediatric patients]
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Abciximab.
AcenocoumarolThe therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Acenocoumarol.
Alpha-1-proteinase inhibitorAlpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor, human recombinant.
AlteplaseThe therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Alteplase.
Aminocaproic acidThe risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Antihemophilic factor, human recombinant.
AncrodThe therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Ancrod.
AnistreplaseThe therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Anistreplase.
Antithrombin AlfaThe therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Antithrombin Alfa.
Antithrombin III humanThe therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Antithrombin III human.
ApixabanThe therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Apixaban.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
Bioclate / Helixate / Hyate:C / Koate-HP / Kogenate / Monarc-M / ReFacto
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AdvateKit300 [iU]/1mLIntravenousBaxter Healthcare Corporation2010-08-192010-08-19US flag
AdvateInjection, powder, for solution500 IUIntravenousTakeda Manufacturing Austria Ag2016-09-07Not applicableEU flag
AdvatePowder, for solution500 unit / vialIntravenousTakedaNot applicableNot applicableCanada flag
AdvateInjection, powder, for solution3000 IUIntravenousTakeda Manufacturing Austria Ag2016-09-07Not applicableEU flag
AdvateInjection, powder, for solution1000 IUIntravenousTakeda Manufacturing Austria Ag2016-09-07Not applicableEU flag
AdvateKit50 [iU]/1mLIntravenousBaxter Healthcare Corporation2010-08-192010-08-19US flag
AdvateInjection, powder, for solution1500 IUIntravenousTakeda Manufacturing Austria Ag2016-09-07Not applicableEU flag
AdvateKit500 [iU]/1mLIntravenousBaxalta US Inc.2012-07-122016-08-26US flag
AdvatePowder, for solution1000 unit / vialIntravenousTakedaNot applicableNot applicableCanada flag
AdvateKit200 [iU]/1mLIntravenousBaxter Healthcare Corporation2003-07-252012-07-12US flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
FANHDI 250 U.I.Antihemophilic factor, human recombinant (250 IU) + Von Willebrand factor human (300 IU)Injection, powder, lyophilized, for solutionIntravenousGRIFOLS BIOLOGICALS LLC.2008-06-192018-05-17Colombia flag
FANHDI 500 U.I.Antihemophilic factor, human recombinant (500 IU) + Von Willebrand factor human (600 IU)Injection, powder, lyophilized, for solutionIntravenousGRIFOLS BIOLOGICALS LLC.2006-11-102019-05-16Colombia flag
FANHDI� 1500 U.I.Antihemophilic factor, human recombinant (1500 IU) + Von Willebrand factor human (1800 IU)Injection, powder, lyophilized, for solutionIntravenousGRIFOLS BIOLOGICALS LLC.2010-11-11Not applicableColombia flag
HAEMATE - P1000 U.I.Antihemophilic factor, human recombinant (1000 IU) + Von Willebrand factor human (2400 IU)Injection, powder, lyophilized, for solutionIntravenousBIOTOSCANA FARMA S.A.2006-11-10Not applicableColombia flag

Categories

ATC Codes
B02BD02 — Coagulation factor viii
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
P89DR4NY54
CAS number
139076-62-3

References

Synthesis Reference

James W. Bloom, "Warm ethanol method for preparation of low fibrinogen antihemophilic factor." U.S. Patent US4478825, issued June, 1955.

US4478825
General References
  1. Titheradge MA, Coore HG: Initial rates of pyruvate transport in mitochondria determined by an "inhibitor-stop" technique. Biochem J. 1975 Sep;150(3):553-6. [Article]
UniProt
P00451
Genbank
M14113
PubChem Substance
46506209
RxNav
1300486
ChEMBL
CHEMBL2108175
PharmGKB
PA164750168
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Antihemophilic_Factor

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedBasic ScienceHemophilia As1
4CompletedOtherHemophilia As1
4CompletedPreventionHemophilia As1
4CompletedTreatmentHematologic Diseases / Hemophilia As1
4CompletedTreatmentHemophilia As8
4CompletedTreatmentSevere Hemophilia A1
4RecruitingTreatmentFactor VIII / Hemophilia As1
4RecruitingTreatmentHemophilia As1
4TerminatedSupportive CareHemophilia As1
4Unknown StatusDiagnosticSevere Hemophilia A1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Baxter International Inc.
  • Bayer Healthcare
  • CSL Behring LLC
  • GlaxoSmithKline Inc.
  • Grifols SA
  • Ipsen Pharmaceuticals Inc.
  • Octapharma USA
  • Talecris Biotherapeutics
  • Wyeth Pharmaceuticals
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntravenous1000 IU
Injection, powder, for solutionIntravenous1500 IU
Injection, powder, for solutionIntravenous2000 IU
Injection, powder, for solutionIntravenous3000 IU
Injection, powder, for solutionIntravenous500 IU
KitIntravenous100 [iU]/1mL
KitIntravenous125 [iU]/1mL
KitIntravenous200 [iU]/1mL
KitIntravenous250 [iU]/1mL
KitIntravenous300 [iU]/1mL
KitIntravenous400 [iU]/1mL
KitIntravenous50 [iU]/1mL
KitIntravenous500 [iU]/1mL
KitIntravenous600 [iU]/1mL
KitIntravenous750 [iU]/1mL
KitIntravenous800 [iU]/1mL
Powder, for solutionIntravenous1500 unit / vial
Powder, for solutionIntravenous3000 unit / vial
Injection, powder, lyophilized, for solutionIntravenous1500 IU
Injection, powder, lyophilized, for solutionIntravenous2000 IU
Injection, powder, lyophilized, for solutionParenteral
PowderParenteral
Injection, powder, lyophilized, for solutionIntravenous100 IU
Injection, powder, for solutionIntravenous; Parenteral
Injection, powder, lyophilized, for solutionIntravenous
Injection, powder, for solutionParenteral5000 IU
Injection, powder, for solutionIntravenous
Injection, solutionIntravenous
Powder, for solutionParenteral
Injection, powder, lyophilized, for solutionIntravenous
Powder, for solutionIntravenous; Parenteral
Injection, powder, lyophilized, for solutionIntravenous1000 IU
Powder, for solutionParenteral
PowderIntravenous
Injection, powder, for solution
KitIntravenous1000 [iU]/2.5mL
KitIntravenous2000 [iU]/5mL
KitIntravenous250 [iU]/2.5mL
KitIntravenous3000 [iU]/5mL
KitIntravenous500 [iU]/2.5mL
Powder, for solutionIntravenous2000 unit / vial
Injection, powder, lyophilized, for solutionIntravenous250 IU
Kit; powder, for solutionIntravenous1000 unit / vial
Kit; powder, for solutionIntravenous2000 unit / vial
Kit; powder, for solutionIntravenous250 unit / vial
Kit; powder, for solutionIntravenous3000 unit / vial
Kit; powder, for solutionIntravenous500 unit / vial
Injection, powder, for solutionIntravenous250 IU
KitIntravenous375 [iU]/1mL
KitIntravenous62.5 [iU]/1mL
Injection, powder, for solutionParenteral
KitIntravenous1000 [iU]/5mL
KitIntravenous1500 [iU]/5mL
KitIntravenous250 [iU]/5mL
KitIntravenous500 [iU]/5mL
Powder, for solutionIntravenous1000 unit / vial
Powder, for solutionIntravenous250 unit / vial
Powder, for solutionIntravenous500 unit / vial
InjectionIntravenous
SolutionIntravenous
Injection, powder, for solutionParenteral
PowderIntravenous500 IU
Injection, powder, lyophilized, for solutionIntravenous500 IU
Injection, powder, for solutionIntravenous1000 iu/1vial
Injection, powder, for solutionIntravenous250 iu/1vial
Injection, powder, for solutionIntravenous500 iu/1vial
Injection, powder, for solution1000 IU
Injection, powder, for solution1500 IU
Injection, powder, for solution250 IU
Injection, powder, for solution500 IU
Prices
Unit descriptionCostUnit
Advate 1201-1800 unit vial1.68USD vial
Advate 1801-2400 unit vial1.68USD vial
Advate 200-400 unit vial1.68USD vial
Advate 2400-3600 unit vial1.68USD vial
Advate 401-800 unit vial1.68USD vial
Advate 801-1200 unit vial1.68USD vial
Kogenate fs 1000 unit vial1.68USD vial
Kogenate fs 250 unit vial1.68USD vial
Kogenate fs 3000 unit vial1.68USD vial
Kogenate fs 500 unit vial1.68USD vial
Xyntha 1000 unit kit1.66USD kit
Xyntha 2000 unit kit1.66USD kit
Xyntha 250 unit kit1.66USD kit
Xyntha 500 unit kit1.66USD kit
Helixate fs 1000 unit vial1.56USD vial
Helixate fs 250 unit vial1.56USD vial
Helixate fs 3000 unit vial1.56USD vial
Helixate fs 500 unit vial1.56USD vial
Wilate 450-450 unit kit1.38USD kit
Wilate 900-900 unit kit1.38USD kit
Hemofil m 1701-2000 unit vial1.34USD vial
Hemofil m 220-400 unit vial1.34USD vial
Hemofil m 401-800 unit vial1.34USD vial
Hemofil m 801-1700 unit vial1.34USD vial
Koate-dvi 1000 unit kit1.31USD kit
Koate-dvi 250 unit kit1.31USD kit
Koate-dvi 500 unit kit1.31USD kit
Refacto 1000 unit vial1.31USD vial
Refacto 2000 unit vial1.31USD vial
Refacto 250 unit vial1.31USD vial
Refacto 500 unit vial1.31USD vial
Alphanate 1000-1500 unit vial1.2USD vial
Alphanate 250-500 unit vial1.2USD vial
Humate-p 1000 unit kit1.2USD kit
Humate-p 1200 unit kit1.2USD kit
Humate-p 2000 unit kit1.2USD kit
Humate-p 2400 unit kit1.2USD kit
Humate-p 500 unit kit1.2USD kit
Humate-p 600 unit kit1.2USD kit
Monoclate-p 1000 unit kit1.01USD kit
Monoclate-p 1500 unit kit1.01USD kit
Monoclate-p 250 unit kit1.01USD kit
Monoclate-p 500ahfu kit1.01USD kit
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
CA2124690No2007-09-112013-10-01Canada flag
CA1339477No1997-09-232014-09-23Canada flag

Properties

State
Solid
Experimental Properties
PropertyValueSource
hydrophobicity-0.533Not Available
isoelectric point6.97Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Activator
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da
References
  1. BLATRIX C, SOULIER JP: [Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)]. Pathol Biol (Paris). 1959 Dec;7:2477-86. [Article]
  2. LUNDBLAD RL, DAVIE EW: THE ACTIVATION OF STUART FACTOR (FACTOR X) BY ACTIVATED ANTIHEMOPHILIC FACTOR (ACTIVATED FACTOR 8). Biochemistry. 1965 Jan;4:113-20. [Article]
  3. Radnoff OD, Saito H: Inhibition of Hageman factor, plasma thromboplastin antecedent, thrombin and other clotting factors by phenylglyoxal hydrate (38500). Proc Soc Exp Biol Med. 1975 Jan;148(1):177-82. [Article]
  4. Orthner CL: Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography. J Lab Clin Med. 1984 Nov;104(5):816-28. [Article]
  5. Freedman J, Mody M, Lazarus AH, Dewar L, Song S, Blanchette VS, Garvey MB, Ofosu FA: Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C). Am J Hematol. 2002 Mar;69(3):192-9. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Cofactor
General Function
Serine-type endopeptidase activity
Specific Function
Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholi...
Gene Name
F9
Uniprot ID
P00740
Uniprot Name
Coagulation factor IX
Molecular Weight
51778.11 Da
References
  1. Hule V: [Factor IX inhibitor (antihemophilic factor B, PTC) in a woman]. Vnitr Lek. 1975 Mar;21(3):274-7. [Article]
  2. Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K: Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985 Jul 2;24(14):3736-50. [Article]
  3. LUNDBLAD RL, DAVIE EW: THE ACTIVATION OF ANTIHEMOPHILIC FACTOR (FACTOR 8) BY ACTIVATED CHRISTMAS FACTOR (ACTIVATED FACTOR9 9). Biochemistry. 1964 Nov;3:1720-5. [Article]
  4. Hoofnagle JH, Gerety RJ, Thiel J, Barker LF: The prevalence of hepatitis B surface antigen in commercially prepared plasma products. J Lab Clin Med. 1976 Jul;88(1):102-13. [Article]
  5. Prince AM, Horowitz B, Brotman B, Huima T, Richardson L, van den Ende MC: Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang. 1984;46(1):36-43. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Binder
General Function
Protein n-terminus binding
Specific Function
Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surf...
Gene Name
VWF
Uniprot ID
P04275
Uniprot Name
von Willebrand factor
Molecular Weight
309261.83 Da
References
  1. Shord SS, Lindley CM: Coagulation products and their uses. Am J Health Syst Pharm. 2000 Aug 1;57(15):1403-17; quiz 1418-20. [Article]
  2. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA: Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002 Feb;87(2):224-30. [Article]
  3. Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA: Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia. 2003 Nov;9(6):688-95. [Article]
  4. Smith KJ, Lusher JM, Cohen AR, Salzman P: Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. Semin Hematol. 1990 Apr;27(2 Suppl 2):25-9. [Article]
  5. Altieri DC, Capitanio AM, Mannucci PM: von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Br J Haematol. 1986 Aug;63(4):703-11. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phytanoyl-coa dioxygenase activity
Specific Function
Converts phytanoyl-CoA to 2-hydroxyphytanoyl-CoA.
Gene Name
PHYH
Uniprot ID
O14832
Uniprot Name
Phytanoyl-CoA dioxygenase, peroxisomal
Molecular Weight
38538.065 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Chen C, Wang Q, Fang X, Xu Q, Chi C, Gu J: Roles of phytanoyl-CoA alpha-hydroxylase in mediating the expression of human coagulation factor VIII. J Biol Chem. 2001 Dec 7;276(49):46340-6. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Carbohydrate binding
Specific Function
Mediates the endocytosis of plasma glycoproteins to which the terminal sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N-...
Gene Name
ASGR2
Uniprot ID
P07307
Uniprot Name
Asialoglycoprotein receptor 2
Molecular Weight
35092.04 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K: The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005 Jun;3(6):1257-65. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Chaperone
General Function
Unfolded protein binding
Specific Function
Probably plays a role in facilitating the assembly of multimeric protein complexes inside the endoplasmic reticulum. Involved in the correct folding of proteins and degradation of misfolded protein...
Gene Name
HSPA5
Uniprot ID
P11021
Uniprot Name
78 kDa glucose-regulated protein
Molecular Weight
72332.425 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Chaperone
General Function
Zinc ion binding
Specific Function
Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently wit...
Gene Name
CALR
Uniprot ID
P27797
Uniprot Name
Calreticulin
Molecular Weight
48141.2 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998 Apr 3;273(14):8537-44. [Article]
  4. Srour MA, Grupp J, Aburubaiha Z, Albert T, Brondke H, Oldenburg J, Schwaab R: Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. Ann Hematol. 2008 Feb;87(2):107-12. Epub 2007 Sep 26. [Article]
  5. Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Chaperone
General Function
Poly(a) rna binding
Specific Function
Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembl...
Gene Name
CANX
Uniprot ID
P27824
Uniprot Name
Calnexin
Molecular Weight
67567.695 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998 Apr 3;273(14):8537-44. [Article]
  4. Becker S, Simpson JC, Pepperkok R, Heinz S, Herder C, Grez M, Seifried E, Tonn T: Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells. Thromb Haemost. 2004 Jul;92(1):23-35. [Article]
  5. Srour MA, Grupp J, Aburubaiha Z, Albert T, Brondke H, Oldenburg J, Schwaab R: Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. Ann Hematol. 2008 Feb;87(2):107-12. Epub 2007 Sep 26. [Article]
  6. Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Chaperone
General Function
Unfolded protein binding
Specific Function
Mannose-specific lectin. May recognize sugar residues of glycoproteins, glycolipids, or glycosylphosphatidyl inositol anchors and may be involved in the sorting or recycling of proteins, lipids, or...
Gene Name
LMAN1
Uniprot ID
P49257
Uniprot Name
Protein ERGIC-53
Molecular Weight
57548.665 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Cunningham MA, Pipe SW, Zhang B, Hauri HP, Ginsburg D, Kaufman RJ: LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost. 2003 Nov;1(11):2360-7. [Article]
  4. Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW: Bioengineering of coagulation factor VIII for improved secretion. Blood. 2004 May 1;103(9):3412-9. Epub 2004 Jan 15. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Modulator
General Function
Receptor activity
Specific Function
Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance...
Gene Name
LRP1
Uniprot ID
Q07954
Uniprot Name
Prolow-density lipoprotein receptor-related protein 1
Molecular Weight
504601.695 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Franchini M, Montagnana M: Low-density lipoprotein receptor-related protein 1: new functions for an old molecule. Clin Chem Lab Med. 2011 Jun;49(6):967-70. doi: 10.1515/CCLM.2011.154. Epub 2011 Mar 11. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Modulator
General Function
Calcium ion binding
Specific Function
The MCFD2-LMAN1 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins. Plays a role in the secretion of coagulation factors.
Gene Name
MCFD2
Uniprot ID
Q8NI22
Uniprot Name
Multiple coagulation factor deficiency protein 2
Molecular Weight
16390.175 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Zhang B, Kaufman RJ, Ginsburg D: LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway. J Biol Chem. 2005 Jul 8;280(27):25881-6. Epub 2005 May 10. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Activator
General Function
Thrombospondin receptor activity
Specific Function
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostas...
Gene Name
F2
Uniprot ID
P00734
Uniprot Name
Prothrombin
Molecular Weight
70036.295 Da
References
  1. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL: Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000 Mar 1;95(5):1694-702. [Article]
  2. Ratnoff OD, Lewis JH: Heckathorn's disease: variable functional dificiency of antihemophilic factor (factor VIII). Blood. 1975 Aug;46(2):161-73. [Article]
  3. Anderson DM, Shelley S, Crick N, Buraglio M: No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol. 2002 Dec;42(12):1358-65. [Article]
  4. Piet MP, Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B: The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion. 1990 Sep;30(7):591-8. [Article]
  5. Lazarchick J, Ashby MA, Lazarchick JJ, Sens DA: Mechanism of factor VIII inactivation by human antibodies. IV. Antibody binding prevents factor VIII proteolysis by thrombin. Ann Clin Lab Sci. 1986 Nov-Dec;16(6):497-501. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inactivator
General Function
Serine-type endopeptidase activity
Specific Function
Protein C is a vitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids (PubMed:25618265). Exerts ...
Gene Name
PROC
Uniprot ID
P04070
Uniprot Name
Vitamin K-dependent protein C
Molecular Weight
52070.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Bereczky Z, Kovacs KB, Muszbek L: Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game. Clin Chem Lab Med. 2010 Dec;48 Suppl 1:S53-66. doi: 10.1515/CCLM.2010.369. Epub 2010 Nov 5. [Article]

Drug created on June 13, 2005 13:24 / Updated on July 28, 2021 07:24